18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet

Frontiers PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions

Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial - The Lancet Oncology

Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial

Application of next-generation imaging in biochemically recurrent prostate cancer

Mask R-CNN assisted 2.5D object detection pipeline of 68Ga-PSMA-11 PET/CT-positive metastatic pelvic lymph node after radical prostatectomy from solely CT imaging

Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance

Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial

PSMA guided approach for bIoCHEmical relapse after prostatectomy‐ (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga‐PSMA PET/CT within a prospective study - Francolini - 2023 - The Prostate - Wiley Online Library